Literature DB >> 21702001

Clinical applications of NGF in ocular diseases.

Alessandro Lambiase1, Flavio Mantelli, Marta Sacchetti, Simona Rossi, Luigi Aloe, Stefano Bonini.   

Abstract

Nerve Growth Factor (NGF) and its receptors TrkA and p75 are expressed in physiological states in the anterior and posterior segments of the human eye, where they exert several tissue-specific functions. The roles played by NGF in the homeostasis of the eye and in vision are, therefore, crucial and have been widely investigated both in vitro and in vivo, with growing evidence of an NGF-pathway alteration in several ocular diseases. In this review we describe the functions of NGF in health and diseases states of the eye, and discuss the potential therapeutic effectiveness of NGF in preliminary clinical reports performed in severe ocular diseases unresponsive to any standard treatment. In fact, pharmacodynamic studies showing that NGF administered topically on the ocular surface affects not only the ocular surface but is also able to reach the retina, optic nerve and brain, recently opened new perspectives for the treatment of challenging ocular surface diseases, optic nerve diseases, and degenerative diseases of the retina currently lacking an effective therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21702001     DOI: 10.4449/aib.v149i2.1363

Source DB:  PubMed          Journal:  Arch Ital Biol        ISSN: 0003-9829            Impact factor:   1.000


  22 in total

1.  The TFOS International Workshop on Contact Lens Discomfort: report of the subcommittee on neurobiology.

Authors:  Fiona Stapleton; Carl Marfurt; Blanka Golebiowski; Mark Rosenblatt; David Bereiter; Carolyn Begley; Darlene Dartt; Juana Gallar; Carlos Belmonte; Pedram Hamrah; Mark Willcox
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-18       Impact factor: 4.799

2.  A comparative study on the transplantation of different concentrations of human umbilical mesenchymal cells into diabetic rats.

Authors:  Jia-Hui Kong; Dan Zheng; Song Chen; Hong-Tao Duan; Yue-Xin Wang; Meng Dong; Jian Song
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

Review 3.  Corneal neurotization for neurotrophic keratopathy: Review of surgical techniques and outcomes.

Authors:  Catherine Y Liu; Andrea C Arteaga; Sammie E Fung; M Soledad Cortina; Ilya M Leyngold; Vinay K Aakalu
Journal:  Ocul Surf       Date:  2021-02-26       Impact factor: 5.033

4.  NGF/anti-VEGF combined exposure protects RCS retinal cells and photoreceptors that underwent a local worsening of inflammation.

Authors:  Maria Luisa Rocco; Bijorn Omar Balzamino; Graziana Esposito; Carla Petrella; Luigi Aloe; Alessandra Micera
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-12-24       Impact factor: 3.117

5.  Dry eye disease: A review of diagnostic approaches and treatments.

Authors:  Hui Lin; Samuel C Yiu
Journal:  Saudi J Ophthalmol       Date:  2014-06-24

Review 6.  Imaging of Uveal Melanoma-Current Standard and Methods in Development.

Authors:  Małgorzata Solnik; Natalia Paduszyńska; Anna M Czarnecka; Kamil J Synoradzki; Yacoub A Yousef; Tomasz Chorągiewicz; Robert Rejdak; Mario Damiano Toro; Sandrine Zweifel; Katarzyna Dyndor; Michał Fiedorowicz
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

7.  Effects of subtenon-injected autologous platelet-rich plasma on visual functions in eyes with retinitis pigmentosa: preliminary clinical results.

Authors:  Umut Arslan; Emin Özmert; Sibel Demirel; Firdevs Örnek; Figen Şermet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-15       Impact factor: 3.117

Review 8.  What can we learn about stroke from retinal ischemia models?

Authors:  Philippe M D'Onofrio; Paulo D Koeberle
Journal:  Acta Pharmacol Sin       Date:  2012-12-03       Impact factor: 6.150

9.  Chronic nerve growth factor exposure increases apoptosis in a model of in vitro induced conjunctival myofibroblasts.

Authors:  Alessandra Micera; Ilaria Puxeddu; Bijorn Omar Balzamino; Stefano Bonini; Francesca Levi-Schaffer
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

10.  Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial.

Authors:  Mauro P Ferrari; Flavio Mantelli; Marta Sacchetti; Maria Irene Antonangeli; Franca Cattani; Gaetano D'Anniballe; Francesco Sinigaglia; Pier Adelchi Ruffini; Alessandro Lambiase
Journal:  BioDrugs       Date:  2014-06       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.